1 week Ago By ABMN Staff
Stock analysts at StockNews.com initiated coverage on shares of Bio-Path ( NASDAQ:BPTH – Get Free Report ) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the stock.
Bio-Path Stock Performance BPTH stock opened at $1.15 on Friday. Bio-Path has a 52-week low of $0.
59 and a 52-week high of $12.00. The stock’s 50 day moving average is $0.
90 and its two-hundred day moving average is $1.22. Institutional Inflows and Outflows A hedge fund recently bought a new stake in Bio-Path stock.
Armistice Capital LLC bought a new position in shares of Bio-Path Holdings, Inc. ( NASDAQ:BPTH – Free Report ) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000.
Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors own 5.
74% of the company’s stock. Bio-Path Company Profile Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter ..
